You are here:Home-Research Areas-Infection-Fungal Infection

Request The Product List ofFungal Infection Fungal Infection

Cat. No. Product Name CAS No. Information
PC-63050

Butenafine hydrochloride

101827-46-7

Butenafine is a synthetic benzylamine antifungal that inhibits the synthesis of ergosterol by inhibiting squalene epoxidase; displays superior activity against Candida albicans than terbinafine and naftifine; demonstrates low MICs against Cryptococcus and Aspergillus.

Fungal Infection

Approved

PC-62617

APX001

936339-60-5

APX001 (APX 001A;E1210) is a novel broad-spectrum antifungal agent that inhibits the fungal protein Gwt1, demonstrates significantly acitive MIC50 and MIC90 values of 0.004 and 0.031 ug/ml (16 strains of C. auris); inhibits the inositol acylation activity of C. albicans Gwt1p and A. fumigatus Gwt1p with IC50 of 0.3 to 0.6 uM but has no inhibitory activity against human Pig-Wp; shows significant efficacy in murine model of disseminated C. auris infection, and log reduction in CFU counts in kidney, lung, and brain tissue.

Fungal Infection

Phase 1 Clinical

PC-62615

PC945

1931946-73-4 PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively; shows MIC values 0.032 to >8 ug/ml against 96 clinically isolated A. fumigatus strains, demonstrates activity against itraconazole-susceptible and -resistant A. fumigatus growth with IC50 of 0.0012 to 0.034 ug/ml; PC945 is a broad spectrum of pathogenic fungi with MIC 0.0078 to 2 ug/ml, and exhibits activity in vivo.

Fungal Infection

Phase 1 Clinical

PC-61753

VT-1161

1340593-59-0 VT-1161 is a potent, highly-selective, and oral fungal CYP51 inhibitor with Kd of ≤ 39 nM; demonstrates >2,000-fold selectivit over human CYP51, weakly inhibits human CYP2C9, CYP2C19, and CYP3A4; exhibits excellent potency against key yeast and dermatophyte strains.

Fungal Infection

Phase 2 Clinical

PC-70224

F-901318

1928707-56-5 A novel antifungal agent that inhibits A. fumigatus DHODH with IC50 of 44 nM; shows little inhibition of human DHODH (>100 uM); displays excellent potency against a broad range of pathogenic filamentous and dimorphic fungi, including Penicillium spp., Coccidiodes immitis, H. capsulatum, Blastomyces dermatitidis, Fusarium spp., and the difficult-to-treat Scedosporium spp.

Fungal Infection

Phase 2 Clinical

PC-60411

SCY-078

1207753-03-4 A novel orally bioavailable fungal beta-1,3-D glucan synthetase inhibitor against Candida species C. glabrata (MIC 0.03 to 0.25 ug/ml), C. parapsilosis (MIC 0.06 to 0.25 ug/ml); shows actvity in an in vivo neutropenic murine model.

Fungal Infection

Phase 3 Clinical

PC-45366

Micafungin

235114-32-6 An echinocandin antifungal drug which can inhibit 1,3-beta-D-glucan synthase.

Fungal Infection

Approved

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com